Personalized Treatment of Recurrent and Metastatic Soft Tissue Sarcoma

The ability to define outcome and thereby design management approaches for rare malignancies is extremely difficult. Soft tissue sarcoma is a group of diverse malignancies with variable presentation, behavior, and outcome. Soft tissue sarcomas are complicated by the fact that they represent at least 100 potentially malignant histological types and subtypes. Of these, 50% are fully malignant and commonly metastasize and 50% are locally aggressive with some but limited metastasis potential. Most soft tissue sarcomas are believed to be sporadic, however in a small proportion of cases genetic factors, lymphedema, and prior radiation therapy have been identified as predisposing or associated factors.

Sarcomas display varying degrees of mesenchymal differentiation, making diagnosis and behavior prediction difficult. This problem is compounded by the nature of these diseases, some with early progression, recurrence and demise and others continuing with multiple recurrences or late recurrences over decades. In this course, you will get an inside look at MSK's approaches to the treatment of recurrent and metastatic soft tissue sarcoma.

1. Understand lessons learned from MSK's study of 10,000 patients with soft tissue sarcoma
2. Understand how MSK uses nomograms to predict the risk of recurrence
3. Discuss the role of surgery in recurrent and metastatic settings
4. Explore the role of external-beam radiation therapy in recurrent and metastatic settings
5. Share current chemo and immunotherapy SoC regimens as well as new agents and clinical trials

This course is complimentary to all registered attendees. Please click on the 'Register' button at the top of this page to sign up. An access link to the join the meeting will be included your registration confirmation email. 

By registering for this live virtual course, you will be able to view presentations, hear live audio, and interact online. CME credit will be offered for this course and a certificate will be available after a post-course evaluation is complete. This live virtual course will be delivered using Zoom. We encourage all attendees to download the Zoom app prior to the start of the course (zoom.us/download). Additional access details will be emailed to all attendees before the course. 

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MSK Course Director 

Sir Murray Brennan, MD, GNZM, FACS
Senior VP, International Programs
Director, The Bobst International Center
Chairman Emeritus, Department of Surgery
Benno C. Schmidt Chair in Clinical Oncology

MSK Course Faculty 

Kaled Alektiar, MD, FASTRO
Attending Radiation Oncologist
Radiation Oncology Service

Mrinal M. Gounder, MD
Associate Attending Oncologist 
Sarcoma Medical Oncology Service

Faculty Disclosures 

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Kaled Alektiar, MD
MSK

Faculty

Nothing to disclose

Murray Brennan, MD
MSK

Faculty

Nothing to disclose

Mrinal Gounder, MD
MSK

Faculty

Consulting Fee-Epizyme|Consulting Fee-Bayer Corporation|Consulting Fee-Karyopharm|Consulting Fee-Springwork Therapeutics|Consulting Fee-Daiichi Sankyo|Consulting Fee-Amgen|Consulting Fee-Springwork Therapeutics

Samuel Singer, MD
MSK

Faculty

Nothing to disclose

Friday, October 16, 2020